Saga, Japan

Tatsuro Watanabe


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Tatsuro Watanabe

Introduction

Tatsuro Watanabe is a notable inventor based in Saga, Japan. He has made significant contributions to the field of medicine, particularly in developing therapeutic agents for cancer treatment. His work focuses on addressing challenges associated with TKI-resistant chronic myeloid leukemia (CML).

Latest Patents

Watanabe holds a patent for the use of a DNMT inhibitor. This invention aims to provide a compound as a therapeutic or prophylactic agent for TKI-resistant CML, serving as a replacement for the injection “Dacogen®.” This compound demonstrates remarkable stability against cytidine deaminase and can be absorbed in vivo through oral administration. It is incorporated into the biosynthesis route of nucleic acid and effectively inhibits DNA methyltransferase (DNMT).

Career Highlights

Throughout his career, Tatsuro Watanabe has worked with esteemed organizations such as Ohara Pharmaceutical Co., Ltd. and Saga University. His experience in these institutions has contributed to his expertise in pharmaceutical research and development.

Collaborations

Watanabe has collaborated with Yuki Kurahashi, enhancing the scope and impact of his research endeavors.

Conclusion

Tatsuro Watanabe's innovative work in developing therapeutic agents for TKI-resistant CML showcases his dedication to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his patent reflects a significant step forward in treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…